Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.74
CBPO's Cash to Debt is ranked higher than
54% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CBPO: 0.74 )
CBPO' s 10-Year Cash to Debt Range
Min: 0.74   Max: 306.77
Current: 0.74

0.74
306.77
Equity to Asset 0.45
CBPO's Equity to Asset is ranked higher than
58% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBPO: 0.45 )
CBPO' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.67
Current: 0.45

0.29
0.67
Interest Coverage 76.59
CBPO's Interest Coverage is ranked higher than
57% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 76.59 )
CBPO' s 10-Year Interest Coverage Range
Min: 6.9   Max: 93.8
Current: 76.59

6.9
93.8
F-Score: 4
Z-Score: 5.12
M-Score: -1.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 42.75
CBPO's Operating margin (%) is ranked higher than
98% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CBPO: 42.75 )
CBPO' s 10-Year Operating margin (%) Range
Min: 21.04   Max: 51.58
Current: 42.75

21.04
51.58
Net-margin (%) 26.85
CBPO's Net-margin (%) is ranked higher than
95% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CBPO: 26.85 )
CBPO' s 10-Year Net-margin (%) Range
Min: 1.86   Max: 26.85
Current: 26.85

1.86
26.85
ROE (%) 22.97
CBPO's ROE (%) is ranked higher than
96% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CBPO: 22.97 )
CBPO' s 10-Year ROE (%) Range
Min: 4.44   Max: 36.52
Current: 22.97

4.44
36.52
ROA (%) 13.52
CBPO's ROA (%) is ranked higher than
96% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CBPO: 13.52 )
CBPO' s 10-Year ROA (%) Range
Min: 1.28   Max: 24.56
Current: 13.52

1.28
24.56
ROC (Joel Greenblatt) (%) 65.32
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. CBPO: 65.32 )
CBPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 39.87   Max: 212.58
Current: 65.32

39.87
212.58
Revenue Growth (%) 8.50
CBPO's Revenue Growth (%) is ranked higher than
82% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CBPO: 8.50 )
CBPO' s 10-Year Revenue Growth (%) Range
Min: 8.3   Max: 57.5
Current: 8.5

8.3
57.5
EBITDA Growth (%) 5.50
CBPO's EBITDA Growth (%) is ranked higher than
85% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CBPO: 5.50 )
CBPO' s 10-Year EBITDA Growth (%) Range
Min: 5.5   Max: 72.3
Current: 5.5

5.5
72.3
EPS Growth (%) 15.10
CBPO's EPS Growth (%) is ranked higher than
90% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CBPO: 15.10 )
CBPO' s 10-Year EPS Growth (%) Range
Min: 6.7   Max: 156.1
Current: 15.1

6.7
156.1
» CBPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CBPO Guru Trades in Q2 2013

Jim Simons 84,800 sh (+22.01%)
Chuck Royce 2,900 sh (unchged)
» More
Q3 2013

CBPO Guru Trades in Q3 2013

Jim Simons 94,500 sh (+11.44%)
Chuck Royce 2,900 sh (unchged)
» More
Q4 2013

CBPO Guru Trades in Q4 2013

Jim Simons 118,400 sh (+25.29%)
Chuck Royce 2,900 sh (unchged)
» More
Q1 2014

CBPO Guru Trades in Q1 2014

Jim Simons 130,375 sh (+10.11%)
Chuck Royce 2,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CBPO



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.50
CBPO's P/E(ttm) is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 21.50 )
CBPO' s 10-Year P/E(ttm) Range
Min: 2.92   Max: 124.23
Current: 21.5

2.92
124.23
P/B 5.77
CBPO's P/B is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. CBPO: 5.77 )
CBPO' s 10-Year P/B Range
Min: 0.84   Max: 6.06
Current: 5.77

0.84
6.06
P/S 6.01
CBPO's P/S is ranked higher than
84% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. CBPO: 6.01 )
CBPO' s 10-Year P/S Range
Min: 0.68   Max: 6.31
Current: 6.01

0.68
6.31
PFCF 30.99
CBPO's PFCF is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 30.99 )
CBPO' s 10-Year PFCF Range
Min: 1.92   Max: 32.54
Current: 30.99

1.92
32.54
EV-to-EBIT 13.12
CBPO's EV-to-EBIT is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 13.12 )
CBPO' s 10-Year EV-to-EBIT Range
Min: 1.2   Max: 15.2
Current: 13.12

1.2
15.2
PEG 1.31
CBPO's PEG is ranked higher than
98% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.31 )
CBPO' s 10-Year PEG Range
Min: 0.41   Max: 1.37
Current: 1.31

0.41
1.37
Shiller P/E 44.33
CBPO's Shiller P/E is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 44.33 )
CBPO' s 10-Year Shiller P/E Range
Min: 27.89   Max: 46.45
Current: 44.33

27.89
46.45
Current Ratio 2.84
CBPO's Current Ratio is ranked higher than
66% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CBPO: 2.84 )
CBPO' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.78
Current: 2.84

1.03
5.78
Quick Ratio 1.72
CBPO's Quick Ratio is ranked higher than
60% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CBPO: 1.72 )
CBPO' s 10-Year Quick Ratio Range
Min: 0.54   Max: 3.92
Current: 1.72

0.54
3.92

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.07
CBPO's Price/Tangible Book is ranked higher than
77% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. CBPO: 6.07 )
CBPO' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 24.65
Current: 6.07

1.16
24.65
Price/DCF (Projected) 1.74
CBPO's Price/DCF (Projected) is ranked higher than
97% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.74 )
CBPO' s 10-Year Price/DCF (Projected) Range
Min: 0.99   Max: 1.33
Current: 1.74

0.99
1.33
Price/Median PS Value 3.12
CBPO's Price/Median PS Value is ranked higher than
66% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CBPO: 3.12 )
CBPO' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 2.38
Current: 3.12

0.46
2.38
Price/Peter Lynch Fair Value 1.31
CBPO's Price/Peter Lynch Fair Value is ranked higher than
99% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.31 )
CBPO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51   Max: 1
Current: 1.31

0.51
1
Price/Graham Number 1.91
CBPO's Price/Graham Number is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.91 )
CBPO' s 10-Year Price/Graham Number Range
Min: 0.36   Max: 4.44
Current: 1.91

0.36
4.44
Earnings Yield (Greenblatt) 7.60
CBPO's Earnings Yield (Greenblatt) is ranked higher than
76% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. CBPO: 7.60 )
CBPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.6   Max: 84.3
Current: 7.6

6.6
84.3
Forward Rate of Return (Yacktman) 18.87
CBPO's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. CBPO: 18.87 )
CBPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 19.2   Max: 35.7
Current: 18.87

19.2
35.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0CB.Germany
China Biologic Products, Inc., is a biopharmaceutical company. It is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products like human albumin and immunoglobulin products in China.
» More Articles for NAS:CBPO

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 
China Biologic Products Amends Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biol Dec 18 2008 

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 25 2014
China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% Jul 09 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Regulation FD Disclosure Jul 07 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 27 2014
China Biologic Announces Pricing of Public Offering of Common Stock Jun 27 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 23 2014
China Biologic Announces Favorable Reduction in Value Added Tax Rate Jun 23 2014
INVESTOR ALERT - The Law Offices of Vincent Wong Investigating Legg Mason Inc. (LM), Banc of... Jun 20 2014
China Biologic Products (CBPO) in Focus: Stock Plunges 11.4% Jun 19 2014
China Biologic files to sell 3.22M shares of common stock Jun 17 2014
China Biologic Announces Proposed Public Offering of Common Stock Jun 17 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Other Events Jun 06 2014
China Biologic initiated with a Buy at Jefferies May 22 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 15 2014
CHINA BIOLOGIC PRODUCTS, INC. Financials May 14 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 08 2014
China Biologic Products' (CBPO) CEO Xiaoying Gao on Q1 2014 Results - Earnings Call Transcript May 07 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 06 2014
China Biologic Reports Financial Results for the First Quarter of 2014 May 06 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 10-Q, Quarterly Report May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide